Nippon Shinyaku to start phase 2 clinical study of NS-065
Nippon Shinyaku Co Ltd:Submitted to the Food and Drug Administration (FDA) on March 25, 2016, an Investigational New Drug (IND) Application for a phase 2 clinical study of NS-065, the first antisense oligonucleotide discovered in Japan for the treatment of Duchenne Muscular Dystrophy (DMD).
Latest Developments forNippon Shinyaku Co Ltd
Latest Key Developments inPharmaceuticals
- Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria
- CO.DON CEO Resigns From Year-End 2017
- Zhejiang Shapuaisi Pharma's Share Trade To Resume After Responding To Regulator's Queries
- IntelGenx Receives Health Canada Clearance To Begin Phase 2a Study With Montelukast Versafilm